Is Retatrutide FDA Approved? Where the Approval Process Stands

No. As of September 29, 2026, retatrutide is not FDA-approved, and FDA states that it cannot be used in compounding under federal law. Majesta Health does not offer, prescribe or sell retatrutide.

Retatrutide is an investigational compound from Eli Lilly and Company, registered on ClinicalTrials.gov under the code LY3437943. Each answer below comes from a primary source read on September 29, 2026: FDA databases and web pages, federal regulations and statute, the federal trial registry, and Lilly's press releases, quoted as the company's own statements.

This page explains status only. It does not describe amounts, trial results or where to buy the substance. For what retatrutide is and why people call it reta, see what retatrutide is.

*What this guide covers:*

• Whether retatrutide is FDA approved, in FDA's words and Lilly's
• What three FDA databases return for retatrutide, and how to read an empty result
• What Lilly has said about applying for approval
• Whether any approval date is public
• What happens between an application and an FDA decision
• Whether a compounding pharmacy can make it
• What FDA says about products labeled for research use
• What expanded access is, and the one expanded access record for retatrutide
• What an approval would and would not change

Retatrutide status by source, September 29, 2026

Is retatrutide FDA approved?

No. On September 29, 2026, no FDA database searched for this page held an approval record or an FDA-approved label for retatrutide.

FDA addresses retatrutide by name on its page about unapproved GLP-1 drugs used for weight loss, content current as of 09/01/2026. The page states: "Retatrutide and cagrilintide cannot be used in compounding under federal law".

In its next sentence, FDA adds: "Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition".

The manufacturer says the same about its own molecule. Lilly's release of July 23, 2026 states: "Retatrutide is an investigational molecule that cannot be legally sold or marketed for human use." Lilly's release of August 12, 2026 states: "No medicine containing retatrutide has yet been approved for human use by any regulatory agency in the world. It cannot be sold to consumers."

Investigational means the compound is still under study in clinical trials. It has not completed FDA review, and there is no FDA-approved prescribing information for it.

What do the FDA databases show for retatrutide?

Three public FDA data sets answer the question, and anyone can repeat the searches. The addresses are in the source list below.

Drugs@FDA. The openFDA service describes this data set in its own words: "Drugs@FDA includes most of the drug products approved since 1939." A search for products with retatrutide as an active ingredient, api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22RETATRUTIDE%22&limit=1, returned {"error":{"code":"NOT_FOUND","message":"No matches found!"}} on September 29, 2026. Because Drugs@FDA describes approved products, it answers the approval question. It cannot show whether an application is pending.

Drug labels. A search of the openFDA label database for the generic name retatrutide, api.fda.gov/drug/label.json?search=openfda.generic_name:%22retatrutide%22&limit=1, returned the same "No matches found!" message. A free-text search of that label database for the word retatrutide did return 12 documents. They are listings other companies submitted, not prescribing information for an FDA-approved product, and this page does not name them.

National Drug Code data. A search of the openFDA NDC data for the generic name retatrutide returned 12 listings on September 29, 2026. All 12 are bulk ingredient listings, meaning raw ingredient rather than a finished medicine. Eleven carry the marketing category "BULK INGREDIENT" and one, with a marketing start date of September 1, 2026, carries "BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING".

A listing is not an approval. FDA's National Drug Code Directory page, content current as of 03/04/2026, states: "Assignment of an NDC number does not in any way denote FDA approval of the product. Any representation that creates an impression of FDA approval because a product has an NDC number is misleading and violates federal law." The same FDA page adds that "The content of each NDC Directory entry is the responsibility of the labeler submitting the SPL file." A category chosen by the company that files a listing does not change FDA's statement that retatrutide cannot be used in compounding under federal law.

Has Lilly applied for FDA approval?

Lilly's release of July 23, 2026 describes the application as planned, not submitted. It states: "Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027." Later in the same release, the company adds: "Lilly is completing the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application (BLA) and plans to subsequently submit retatrutide in Q1 2027 for U.S. approval."

The release also reports trial results, which this page does not reproduce.

Lilly's release of September 15, 2026, about data presented at the EASD 2026 meeting, names retatrutide and does not announce a submission. This page reports the plan as Lilly stated it and does not predict how FDA will handle it.

What the public record does show is the research program behind the plan. ClinicalTrials.gov listed 33 retatrutide records on September 29, 2026, including 14 phase 3 records: 5 Completed, 8 Active, not recruiting, and 1 Recruiting. None of the 14 phase 3 records has posted results on the registry.

When will retatrutide be FDA approved?

No FDA decision date is public. The only date on the public record is Lilly's plan to submit its application in Q1 2027, and that is a company plan, not an FDA schedule.

No FDA source read for this page gives a decision date, a review goal date or an availability date for retatrutide. Any date quoted elsewhere for approval, release or availability is a forecast by whoever quotes it. This page gives none.

What happens between an application and an approval?

FDA explains the review in its patient page "Step 4: FDA Drug Review", content current as of 01/04/2018. FDA writes: "The FDA review team thoroughly examines all submitted data on the drug and makes a decision to approve or not to approve it."

That FDA page describes the steps for a new drug application:

1. Filing review. "Once FDA receives an NDA, the review team decides if it is complete. If it is not complete, the review team can refuse to file the NDA."
2. Section reviews. "Each member of the review team conducts a full review of his or her section of the application."
3. Site inspections. "FDA inspectors travel to clinical study sites to conduct a routine inspection."
4. Decision. "The review team issues a recommendation, and a senior FDA official makes a decision."
5. Labeling. When FDA finds a drug has met the standard, FDA says "it is then necessary to work with the applicant to develop and refine prescribing information. This is referred to as 'labeling.'"

Approval is not the only outcome. The same FDA page states: "Often, though, remaining issues need to be resolved before the drug can be approved for marketing. Sometimes FDA requires the developer to address questions based on existing data. In other cases, FDA requires additional studies."

Lilly named a different application type, the Biologics License Application, and federal regulations set its terms. Under 21 CFR 601.2(a), the manufacturer submits "data derived from nonclinical laboratory and clinical studies which demonstrate that the manufactured product meets prescribed requirements of safety, purity, and potency." Under 21 CFR 601.4(a), "A biologics license shall be issued upon a determination by the Director, Center for Biologics Evaluation and Research or the Director, Center for Drug Evaluation and Research that the establishment(s) and the product meet the applicable requirements established in this chapter." Under 601.4(b), if FDA finds the requirements are not met, "the biologics license application shall be denied and the applicant shall be informed of the grounds for, and of an opportunity for a hearing on, the decision."

This page does not give review lengths. They depend on the application type and the review path, and no FDA source read for this page states one for retatrutide.

Can a compounding pharmacy make retatrutide?

No, according to FDA. Its page on unapproved GLP-1 drugs states: "Retatrutide and cagrilintide cannot be used in compounding under federal law."

The statute sets the conditions. Under 21 U.S.C. 353a, the section that governs pharmacy compounding, bulk drug substances used by a pharmacist must, among other requirements, meet one of three conditions: they "comply with the standards of an applicable United States Pharmacopoeia or National Formulary monograph, if a monograph exists"; or, "if such a monograph does not exist, are drug substances that are components of drugs approved by the Secretary"; or they appear on a list FDA develops through regulations. FDA's statement that retatrutide is "not components of FDA-approved drugs" matches the wording of that second condition; FDA's page does not cite the statute.

FDA's page also lists the parties it has warned. The agency writes that it has warned "Telehealth companies for marketing unapproved drugs such as retatrutide, including instances of direct marketing to consumers", "Active pharmaceutical ingredient distributors for selling retatrutide and other GLP-1 drugs to compounders" and "Outsourcing facilities for repackaging retatrutide."

For how pharmacies and outsourcing facilities differ under federal law, see 503A vs 503B pharmacy. Compounded medications are not FDA-approved as final products.

Is retatrutide sold for research use legal?

FDA calls these sales illegal. Its page on unapproved GLP-1 drugs states: "FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled 'for research purposes' or 'not for human consumption.' These products have been sold directly to consumers for human use with dosing instructions. The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health."

Lilly's position, in its release of July 23, 2026, is that retatrutide "cannot be legally sold or marketed for human use." Its release of August 12, 2026 states: "It cannot be sold to consumers."

A research label does not turn a product into an approved medicine. This page quotes FDA's general statement rather than warning letters that name companies. Whether a particular transaction breaks a particular law is a question for a lawyer.

What is expanded access, and does it apply to retatrutide?

FDA defines it on its Expanded Access page, content current as of 09/08/2025: "Sometimes called 'compassionate use', expanded access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available."

FDA lists conditions that must all apply, including "Patient enrollment in a clinical trial is not possible." The same FDA page is plain about how investigational products differ from FDA-approved ones: "Investigational drugs, biologics or medical devices have not yet been approved or cleared by FDA and FDA has not found these products to be safe and effective for their specific use."

ClinicalTrials.gov holds one expanded access record for retatrutide. NCT07629401 is titled "Pre-approval Expanded Access of Retatrutide (LY3437943)", lists Eli Lilly and Company as sponsor, is registered as individual (single-patient) expanded access and showed the status Available on September 29, 2026. Its summary describes adults with severe obesity and at least two serious or life-threatening obesity-related complications who are "refractory to the best approved therapy and are unable to participate in an ongoing clinical trial of retatrutide or a comparable investigational medicine."

Expanded access is a case-by-case exception under FDA oversight. It is not an approval, and the record's own title says pre-approval.

What would change if FDA approves retatrutide?

If FDA approves an application, the public record would change in ways FDA's own pages describe. There would be FDA-approved labeling, which FDA says "accurately and objectively describes the basis for approval and how best to use the drug." The approved product would become the kind of product Drugs@FDA describes, and its prescribing information would be public. The questions this page cannot answer today, such as which patients the approved product is for and what its label warns about, would then have an answer in FDA-approved labeling. What the trial record says so far is in retatrutide side effects.

Some things would not change. An approval covers the product named in the application: under 21 CFR 601.4(a) a license follows a determination that "the establishment(s) and the product" meet the requirements. An approval would not turn a product labeled for research use into an approved medicine.

This page does not predict whether or when an approval will happen, or how one would affect compounding rules. The status facts here will be rechecked against the same primary sources at least every 90 days and after any FDA action or Lilly filing announcement. For how to read a label, see how to read a prescription label; for the drug class, what a GLP-1 medication is.

What the primary sources say

• U.S. Food and Drug Administration, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content current as of 09/01/2026 (accessed September 29, 2026): "Retatrutide and cagrilintide cannot be used in compounding under federal law."; "Telehealth companies for marketing unapproved drugs such as retatrutide, including instances of direct marketing to consumers."; "FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled 'for research purposes' or 'not for human consumption.'"
• U.S. Food and Drug Administration, openFDA Drugs@FDA and drug label APIs (accessed September 29, 2026): {"error":{"code":"NOT_FOUND","message":"No matches found!"}} for retatrutide as an active ingredient and as a generic name
• openFDA, Drugs@FDA API overview (accessed September 29, 2026): "Drugs@FDA includes most of the drug products approved since 1939."
• U.S. Food and Drug Administration, National Drug Code Directory, content current as of 03/04/2026 (accessed September 29, 2026): "Assignment of an NDC number does not in any way denote FDA approval of the product."; "Inclusion in the NDC Directory does not indicate that FDA has verified the information provided or that the products are FDA-approved."
• U.S. Food and Drug Administration, Step 4: FDA Drug Review, content current as of 01/04/2018 (accessed September 29, 2026): "The FDA review team thoroughly examines all submitted data on the drug and makes a decision to approve or not to approve it."
• Electronic Code of Federal Regulations, 21 CFR 601.4, up to date as of September 25, 2026 (accessed September 29, 2026): "A biologics license shall be issued upon a determination by the Director, Center for Biologics Evaluation and Research or the Director, Center for Drug Evaluation and Research that the establishment(s) and the product meet the applicable requirements established in this chapter."
• Office of the Law Revision Counsel, 21 U.S.C. 353a(b)(1)(A)(i) (accessed September 29, 2026): "if such a monograph does not exist, are drug substances that are components of drugs approved by the Secretary"
• U.S. Food and Drug Administration, Expanded Access, content current as of 09/08/2025 (accessed September 29, 2026): "expanded access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available."
• ClinicalTrials.gov, record NCT07629401 (accessed September 29, 2026): "Pre-approval Expanded Access of Retatrutide (LY3437943)", overall status Available
• Eli Lilly and Company, press release of July 23, 2026, via PR Newswire (accessed September 29, 2026): "Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027"; "Retatrutide is an investigational molecule that cannot be legally sold or marketed for human use."
• Eli Lilly and Company, press release of August 12, 2026, via PR Newswire (accessed September 29, 2026): "No medicine containing retatrutide has yet been approved for human use by any regulatory agency in the world. It cannot be sold to consumers."

Every source is listed with its address below.

This article is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational compound with no FDA-approved label; nothing here recommends its use or describes where to buy it. Status facts were read from the primary sources named above on September 29, 2026, and Lilly's statements are quoted as the company's own. Majesta Health does not offer, prescribe or sell retatrutide. Medication is prescribed only if a licensed physician determines it is appropriate.